Jiang Qian, Yang Xiawei, Deng Teng, Yan Jun, Guo Fangzhou, Mo Ligen, An Sanqi, Huang Qianrong
Department of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Transplant Medical Center, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Mol Ther Oncol. 2024 Jun 17;32(3):200838. doi: 10.1016/j.omton.2024.200838. eCollection 2024 Sep 19.
In this study, we developed a new prognostic model for glioblastoma (GBM) based on an integrated machine learning algorithm. We used univariate Cox regression analysis to identify prognostic genes by combining six GBM cohorts. Based on the prognostic genes, 10 machine learning algorithms were integrated into 117 algorithm combinations, and the artificial intelligence prognostic signature (AIPS) with the greatest average C-index was chosen. The AIPS was compared with 10 previously published models by univariate Cox analysis and the C-index. We compared the differences in prognosis, tumor immune microenvironment (TIME), and immunotherapy sensitivity between the high and low AIPS score groups. The AIPS based on the random survival forest algorithm with the highest average C-index (0.868) was selected. Compared with the previous 10 prognostic models, our AIPS has the highest C-index. The AIPS was closely linked to the clinical features of GBM. We discovered that patients in the low score group had improved prognoses, a more active TIME, and were more sensitive to immunotherapy. Finally, we verified the expression of several key genes by western blotting and immunohistochemistry. We identified an ideal prognostic signature for GBM, which might provide new insights into stratified treatment approaches for GBM patients.
在本研究中,我们基于集成机器学习算法开发了一种新的胶质母细胞瘤(GBM)预后模型。我们通过合并六个GBM队列,使用单变量Cox回归分析来识别预后基因。基于这些预后基因,将10种机器学习算法整合为117种算法组合,并选择平均C指数最高的人工智能预后特征(AIPS)。通过单变量Cox分析和C指数将AIPS与10种先前发表的模型进行比较。我们比较了高AIPS评分组和低AIPS评分组在预后、肿瘤免疫微环境(TIME)和免疫治疗敏感性方面的差异。选择了基于平均C指数最高(0.868)的随机生存森林算法的AIPS。与之前的10种预后模型相比,我们的AIPS具有最高的C指数。AIPS与GBM的临床特征密切相关。我们发现低评分组患者的预后更好,TIME更活跃,并且对免疫治疗更敏感。最后,我们通过蛋白质免疫印迹法和免疫组织化学法验证了几个关键基因的表达。我们确定了一种理想的GBM预后特征,这可能为GBM患者的分层治疗方法提供新的见解。